SCHEMBL7647149

SCHEMBL7647149

O=S(=O)(c1cccc(F)c1)N1CC[CH]CC1

nearest known ligand 0.59

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PKM P14618 3/20 0.59
PKLR P30613 1/20 0.59
KMT2A Q03164 4/20 0.54
MEN1 O00255 3/20 0.54
TDP1 Q9NUW8 1/20 0.54
GFER P55789 1/20 0.54
SMN1; SMN2 Q16637 2/20 0.53
HTR2A P28223 1/20 0.53
HTR2C P28335 1/20 0.53
GPR183 P32249 1/20 0.52
ALDH1A1 P00352 2/20 0.51
USP2 O75604 1/20 0.51
RAB9A P51151 1/20 0.50
MAPK1 P28482 1/20 0.50
LMNA P02545 1/20 0.50
TSHR P16473 1/20 0.50
NPC1 O15118 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31315849 0.90 PKM (0.70) PKMPKLRKMT2AMEN1TDP1
SCHEMBL14489550 0.86 ALDH1A1 (0.69) PKMPKLRKMT2AMEN1TDP1
SCHEMBL28308929 0.85 ALDH1A1 (0.67) PKMPKLRKMT2AMEN1SMN1; SMN2
SCHEMBL31684030 0.85 ALDH1A1 (0.67) PKMPKLRKMT2AMEN1SMN1; SMN2
SCHEMBL4555427 0.85 ALDH1A1 (0.67) PKMPKLRKMT2AMEN1SMN1; SMN2
SCHEMBL30754642 0.82 TDO2 (0.60) PKMPKLRKMT2AMEN1TDP1
SCHEMBL29779559 0.82 PKM (0.58) PKMPKLRKMT2AMEN1TDP1
SCHEMBL19348507 0.82 PKM (0.58) PKMPKLRKMT2AMEN1TDP1
SCHEMBL29483599 0.82 PKM (0.66) PKMPKLRKMT2AMEN1SMN1; SMN2
Hydrochloric Acid SCHEMBL1180727 0.81 TDO2 (0.59) PKMPKLRKMT2AMEN1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010041714-A1 5-HT7 receptor antagonists CAIN GARY A (US) 2001-11-15 US claimed
US-6486173-B2 SEROTONIN-7 (5-HT7); TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS SUCH AS SLEEP DISORDERS, DEPRESSION AND SCHIZOPHRENIA; FOR EXAMPLE 1,3-DIHYDRO-2-((4-(4-FLUOROPHENYL)-4-OXOBUTYL))ISOINDOLE BRISTOL-MYERS SQUIBB PHARMA COMPANY 2002-11-26 US disclosed
US-20010041714-A1 5-HT7 receptor antagonists CAIN GARY A (US) 2001-11-15 US disclosed
US-6239143-B1 TREATMENT CNS DISORDERS SUCH AS ANXIETY, DEPRESSION, SLEEP DISORDERS, AND SCHIZOPHRENIA. DUPONT PHARMACEUTICALS COMPANY 2001-05-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010041714-A1 5-HT7 receptor antagonists HTR7, HTR5A, HTR1A PKM 3479/4885PKLR 3926/4885KMT2A 3243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.